Clinical Trial: QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07716449) titled 'QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ' on July 16.

Brief Summary: This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS < 5 unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Gastric or Gastroesophageal Junction Adenocarcinoma

Inter...